The BioCentury Show
Episodes
Ep. 106 - Can the U.K. Capture Biotech Value? Daniel Mahony on Growth, Pricing and Reform
03 Apr 2026
Contributed by Lukas
The U.K. is excellent at invention and science, and creating institutions to further innovation, but poor at capturing their economic value, says Dani...
Ep. 105 - Recursion’s Najat Khan: AI Will Be Judged by the Medicines It Delivers
20 Mar 2026
Contributed by Lukas
As AI spreads across biopharma, what will matter most is not who has the flashiest tools, but who can use them to make better medicines. In this episo...
Ep. 104 - SoftBank’s Jacqueline Fok on AI Drug Development, Metsera and the U.K. Biotech Opportunity
06 Mar 2026
Contributed by Lukas
There is a real opportunity for artificial intelligence to dramatically transform the speed, cost and efficiency of drug development over the long ter...
Ep. 103 - RA Capital's Peter Kolchinsky
18 Feb 2026
Contributed by Lukas
In a candid interview with BioCentury, RA Capital Managing Partner Peter Kolchinsky warns that staffing losses and growing conservatism at FDA are slo...
Ep. 102 - Psychiatry R&D: Steve Paul on Serendipity, Engineering and What Drives Real Breakthroughs
06 Feb 2026
Contributed by Lukas
With disease biology still murky and trials notoriously noisy, psychiatry R&D is advancing fastest where teams can solve engineering problems. Del...
Ep. 101 - Why Science Stalls: Astellas CEO Naoki Okamura on Translation, Talent and Platforms
23 Jan 2026
Contributed by Lukas
Why does great science so often stall before it becomes a medicine? Astellas Pharma CEO Naoki Okamura argues the bottleneck isn’t capital — it’s...
Ep. 100 - Bain Capital’s Adam Koppel on Private Equity, Scaled Biotech Deals and the 2026 Outlook
09 Jan 2026
Contributed by Lukas
View full story: https://www.biocentury.com/article/657997#PrivateEquity #BiotechDeals #LifeSciencesInvesting #GrowthEquity #BiopharmaMarkets00:00 - I...
Ep. 99 – Stelios Papadopoulos on Biotech’s Long View: Pricing Pressure, China & Big Pharma
19 Dec 2025
Contributed by Lukas
In historical terms, this is not a bear market, says Stelios Papadopoulos. There’s volatility, which is unnerving, and major issues to reckon with, ...
Ep. 98 - Inside Precision Oncology’s Next Chapter with Fore’s Bill Hinshaw
05 Dec 2025
Contributed by Lukas
When Bill Hinshaw looks back across the arc of his career — from his early days helping to commercialize Gleevec to his present role leading Fore Bi...
Popular Episode - Reimagining FDA: Steve Usdin on Designing the Drug Regulator of the Future
27 Nov 2025
Contributed by Lukas
This is a previously recorded episode of The BioCentury Show from September 5, 2025. Subscribe to this channel to listen to each new episode. Visit Th...
Ep. 97 – From NIH to Industry: Zerhouni Warns Policy & Rhetoric Threaten U.S. Science
14 Nov 2025
Contributed by Lukas
Elias Zerhouni personifies the American dream. He arrived in the U.S. from Algeria as a young man with a couple of hundred dollars in his pocket. Tale...
Ep. 96 – From Pharma Partnering to Biotech CEO: Sophie Kornowski on Boston Pharma’s Playbook
31 Oct 2025
Contributed by Lukas
It took Sophie Kornowski under four years as CEO of Boston Pharma to bring it from a pipeline full of in-licensed assets to an acquisition by GSK for ...
Ep. 95 - Kymera CEO Nello Mainolfi: Matching Degrader Chemistry to the Problem
16 Oct 2025
Contributed by Lukas
Kymera Therapeutics has a clear mission: to transform immunology with targeted protein degraders that enable “oral drugs with biologics-like activit...
Ep. 94 - Frazier's James Li on China’s Rapidly Evolving Biotech Deal Landscape
03 Oct 2025
Contributed by Lukas
The frenzy among Western companies to access China’s biotechnology innovation is remaking the landscape for cross-border dealmaking, with assets bec...
Ep. 93 – BIO’s Fritz Bittenbender on Trump 2.0, MFN Threats & Pharma’s Concessions
18 Sep 2025
Contributed by Lukas
President Donald Trump’s demands for “most favored nation” drug pricing presents the biopharma industry with an immense public policy challenge....
Ep. 92 - Reimagining FDA: Steve Usdin on Designing the Drug Regulator of the Future
06 Sep 2025
Contributed by Lukas
If you could redesign FDA from the ground up, what would it look like? That’s the fundamental question underlying the 2025 BioCentury Back to School...
Ep. 91 – Annalisa Jenkins: How MHRA’s Reset Could Revive U.K. Biotech
22 Aug 2025
Contributed by Lukas
A new head at MHRA, a streamlined government life sciences strategy, and a more sophisticated innovation ecosystem have Annalisa Jenkins optimistic ab...
Popular Episode - Vertex’s Winning Formula: Altshuler on Choosing the Next Breakthroughs
13 Aug 2025
Contributed by Lukas
This is a previously recorded episode of The BioCentury Show from March 19, 2025. Subscribe to this channel to listen to each new episode. Visit TheBi...
Ep. 90 – Inside Biopharma Dealmaking: ProFound CEO John Lepore on Knowing What Partners Want
24 Jul 2025
Contributed by Lukas
In an environment where everybody hurts, it helps for biotech CEOs to understand the pressures driving pharmas, investors and other key players if the...
Ep. 89 - Delivering on the biosimilars promise, a conversation with Gillian Woollett
10 Jul 2025
Contributed by Lukas
Gillian Woollett, head of regulatory strategy and policy at Samsung Bioepis, discusses how FDA can deliver on its promise to “massively streamline”...
Ep. 88 – From Satiety to Muscle: Zealand CEO Steensberg on Amylin’s Edge in Obesity
27 Jun 2025
Contributed by Lukas
Mounting clinical evidence suggests amylin agonists could supplant GLP-1 molecules as the foundational backbone of future obesity therapy, says Zealan...
Ep. 87 – Korea’s Biotech Playbook: Orum CEO SJ Lee on Going Global and Creating Novel Therapies
13 Jun 2025
Contributed by Lukas
Globalizing quickly and gaining a first-mover advantage are the winning strategies for South Korean biotechs as they look to compete on the world stag...
Ep. 86 – Macrophages, ASCO & Clever-1: Faron CEO Juho Jalkanen on Bexmarilimab’s Promise
04 Jun 2025
Contributed by Lukas
The macrophage field has seen its share of setbacks, but Faron believes bexmarilimab, its humanized mAb that binds to immune checkpoint target Clever-...
Ep. 85 - Stifel’s Opler on Trump 2.0's FDA & the Capital Markets
29 May 2025
Contributed by Lukas
Notwithstanding the bad start that the Trump administration got off to on FDA, Tim Opler is optimistic that the agency will serve drug developers well...
Ep. 84 – Leadership Amid Turmoil: Moonlake CEO Jorge Santos Da Silva
21 May 2025
Contributed by Lukas
As CEO of a vintage 2021 biotech, Jorge Santos Da Silva has had his leadership mettle tested by a pandemic, rising interest rates, a bear market, and ...
Ep. 83 – Europe’s Biotech Moment: Jérôme van Biervliet on Turning Uncertainty into Opportunity
02 May 2025
Contributed by Lukas
Europe did not ask for this opportunity, says VIB’s Jérôme van Biervliet, but with FDA and the U.S. research funding situation headed into uncerta...
Ep. 82 – Act Now or Fall Behind: Michelle Rozo on Biotech’s National Security Stakes
17 Apr 2025
Contributed by Lukas
The U.S. will cede its preeminence in biotechnology to China within three years unless the government acts urgently, an independent commission charter...
Ep. 81 - Data-Driven Growth: Immunocore CEO Bahija Jallal on Expanding TCR Therapies
04 Apr 2025
Contributed by Lukas
On the latest episode of The BioCentury Show, Editor in Chief Simone Fishburn speaks with Bahija Jallal, CEO of Immunocore and the former president of...
Ep. 80 - Vertex’s Winning Formula: Altshuler on Choosing the Next Breakthroughs
20 Mar 2025
Contributed by Lukas
Vertex’s approach to research, defined over a decade ago to beat the dismal odds of success in biotech, remains core to its strategy, even as the in...
Ep. 79 - BNP Paribas’ Moneer on Biotech’s Bull Case: M&A, PE, and Market Recovery
08 Mar 2025
Contributed by Lukas
Since the annual J.P. Morgan Healthcare Conference in San Francisco in early January, biotech has seen a notable surge in enthusiasm, Zahid Moneer, se...
Ep. 78 - Biotech’s New Normal: SR One’s Simeon George on Adapting to Market Constraints
20 Feb 2025
Contributed by Lukas
Biotechs need to get used to the new normal, says SR One CEO and Managing Partner Simeon George, and that will require significant adjustments to the ...
Ep. 77 - AI’s Next Leap: Foresite Labs’ Vik Bajaj on Predictive Biology
07 Feb 2025
Contributed by Lukas
Clinical trials will be launched in the next year or two to test predictions about causal biology made by artificial intelligence models, Vik Bajaj, c...
Ep. 76 - FDA Inflection Point: Steve Usdin on Biopharma during Trump 2.0
24 Jan 2025
Contributed by Lukas
All presidential transitions with a change of party come with disruption and threats as well as opportunities. But this one, in particular with regard...
Ep. 75 - PBMs, IRA, RFK Jr: A Conversation With Rep. Jake Auchincloss
13 Jan 2025
Contributed by Lukas
Rep. Jake Auchincloss (D-Mass.), an influential voice in Congress on life sciences issues, gained stature last week when he was appointed to serve on ...
Ep. 74 - Chris Bardon on Biotech’s Recovery: Valuations, Obesity Drugs, and M&A
10 Jan 2025
Contributed by Lukas
Specialist public investors are doing their best to hold up the sector, but biotech still has to wash out many of the lower quality companies that wer...
Ep. 73 - Resilience and the CEO’s Paradox: Aoife Brennan on Leading in Biotech
13 Dec 2024
Contributed by Lukas
Leading biotech companies through the turbulence of the past few years and the uncertainty of the next ones takes not just resilience, but an ability ...
Ep. 72 - Outlook for Biotech M&A and Financing: Sidley's Robert Darwin
14 Nov 2024
Contributed by Lukas
With new governments both side of the pond, capital markets picking up, and some geopolitical overhang, there’s a mixed feast for biotech, with a ne...
Ep. 71 - Pazdur Unplugged: FDA Director Richard Pazdur on the Past, Future of Cancer Treatments
31 Oct 2024
Contributed by Lukas
Richard Pazdur, director of FDA’s Oncology Center of Excellence, joined FDA in 1999. Looking back on his 25th anniversary, he draws a line between u...
Ep. 70 - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine
18 Oct 2024
Contributed by Lukas
With most of the highly attractive late-stage assets already scooped up, pharmas are turning their sights to Phase II companies, and lining up their c...
Ep. 69 - Lee Fleisher: An Insider’s Account of CMS’s Alzheimer’s Coverage Decisions
04 Oct 2024
Contributed by Lukas
CMS’s controversial decision to restrict access to Alzheimer’s mAb treatments, including Aduhelm, approved under FDA’s accelerated pathway was a...
Ep. 68 - Inside BeiGene: CEO John Oyler on Owning the Drug Development Process
19 Sep 2024
Contributed by Lukas
Few CEOs have built a $20 billion biotech in under 15 years, as John Oyler has with BeiGene, managing to stay in that market cap band even through the...
Ep 67 - AAM's Craig Burton on Opportunities, Challenges of U.S. Biosimilars Market
05 Sep 2024
Contributed by Lukas
There is good news in this year’s Association for Accessible Medicines report on savings from biosimilars, including a 30% increase over the last ye...
Popular Episode - Bob Nelsen on AI, China and the IRA
22 Aug 2024
Contributed by Lukas
This is a previously recorded episode of The BioCentury Show from February 22, 2024. Subscribe to this channel to listen to each new episode. Visit Th...
Ep. 66 - Jane Grogan on Building Biogen’s Growth Engine
08 Aug 2024
Contributed by Lukas
As Jane Grogan anticipates the unmet needs in patients five years from now, she’s harnessing a wave of interest in targeting B cells as a key driver...
Ep. 65 - Astellas' Claus Zieler: Global Launches with Local Impact
25 Jul 2024
Contributed by Lukas
As Astellas prepares to launch four products in parallel, Chief Commercial Officer Claus Zieler is balancing the complexity of this multi-faceted ente...
Ep. 64 - NPC CEO John O’Brien: Why America Needs an Honest Conversation About Drug Pricing
11 Jul 2024
Contributed by Lukas
Ignorance about the path from scientific discovery to approved drugs, high out-of-pocket costs, and a byzantine healthcare system that obscures net pr...
Ep. 63 - Day One's Jeremy Bender: Building Pediatric Oncology from the Ground Up
27 Jun 2024
Contributed by Lukas
Pediatric cancer drug development is difficult: it requires high levels of safety, involves parents as well as the patients, and has small populations...
Ep. 62 - Rick Bright: Navigating the Avian Flu Threat
13 Jun 2024
Contributed by Lukas
The U.S. is experiencing events that are either the first stages of a widespread avian influenza outbreak or a fire drill that will show how well the ...
Ep. 61 - Vas Narasimhan: How New Data Fit Novartis’ Growth Plan
31 May 2024
Contributed by Lukas
Differentiating on tolerability, raising the bar for efficacy and concentrating small molecule development on indications with minimal IRA exposure ar...
Ep. 60 - JMM John Maraganore: A higher bar for investment is a credit to biotech
30 May 2024
Contributed by Lukas
“The bar has gotten higher because science has gotten so much better,” John Maraganore says on the latest BioCentury Show. Reflecting on the capit...
Ep. 59 - Derek Lowe Unplugged: AI; Biosecure; FDA, Abortion & SCOTUS; and more
16 May 2024
Contributed by Lukas
“I’m a short-term pessimist and a long-term optimist” about the potential for AI to transform drug development, Derek Lowe, author of the In the...
Ep. 58 - Ysios' Karen Wagner: How Europe's Biotechs Can Rise Above the Noise
02 May 2024
Contributed by Lukas
It sounds obvious, but still needs saying, says Ysios Capital's Karen Wagner. “How do you rise above the noise? By having the most spectacular ...
Ep. 57 - BMS's Robert Plenge: Causal biology is the North Star of R&D
02 May 2024
Contributed by Lukas
This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com ...
Ep. 56 - BIO’s John Crowley on the Biosecure Act
17 Apr 2024
Contributed by Lukas
This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com ...
Ep. 55 - Bruce Booth: Biotech Benefiting from Belt-Tightening
17 Apr 2024
Contributed by Lukas
This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com ...
Ep. 54 - Arthur Caplan: Lessons From a Compassionate Use Firestorm
17 Apr 2024
Contributed by Lukas
This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com ...
Ep. 53 - Bob Nelsen on AI, China and the IRA
17 Apr 2024
Contributed by Lukas
This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com ...
Ep. 52 - Khoo Shih on Scaling Singapore Biotech
17 Apr 2024
Contributed by Lukas
This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com ...